Bio-Medical Applications Of Alabama, Inc is a medicare approved dialysis facility center in Birmingham, Alabama and it has 10 dialysis stations. It is located in Jefferson county at 2024 4th Ave South, Suite 100, Birmingham, AL, 35233.
You can reach out to the office of Bio-Medical Applications Of Alabama, Inc at (205) 321-5844. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Bio-Medical Applications Of Alabama, Inc has the following ownership type - Profit. It was first certified by medicare in September, 2016. The medicare id for this facility is 012687 and it accepts patients under medicare ESRD program.
Dialysis Center Profile
| Name | Bio-Medical Applications Of Alabama, Inc |
|---|
| Location | 2024 4th Ave South, Suite 100, Birmingham, Alabama |
|---|
| No. of Dialysis Stations | 10 |
|---|
| Medicare ID | 012687 |
|---|
| Managed By | Fresenius Medical Care |
|---|
| Ownership Type | Profit |
|---|
| Late Shifts | No |
|---|
NPI Associated with this Dialysis Facility:
Dialysis Facilities may have multiple NPI numbers. We have found possible NPI number/s associated with Bio-Medical Applications Of Alabama, Inc
from NPPES records by matching pattern on the basis of name, address, phone number etc.
Please use this information accordingly.
| NPI Number | 1225411739 |
| Organization Name | Fresenius Medical Care Birmingham Metro |
| Doing Business As | Bio-medical Applications Of Alabama, Inc. |
| Address | 2024 4th Ave S Birmingham, Alabama, 35233 |
| Phone Number | (205) 802-1676 |
Patient Distribution
Anemia Management
| Dialysis patients with Hemoglobin data | 6 |
Dialysis Adequacy
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
- Hemodialysis
| Adult patients getting regular hemodialysis at the center | 43 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 124 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
Mineral and Bone Disorder
An important goal of dialysis is to maintain normal levels of various minerals
in the body, such as calcium. This shows the percentage of patients
treated at Bio-Medical Applications Of Alabama, Inc with elevated calcium levels.
| Patients with hypercalcemia | 43 |
| Hypercalcemia patient months | 124 |
| Patients with Serumphosphor | 45 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 33 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 20 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 22 |
| Patients with Serumphosphor greater than 7 mg/dL | 15 |
Vascular Access
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it
allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access.
Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 63 |
| Patient months included in arterial venous fistula and catheter summaries | 180 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 55 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 6 |
Hospitalization Rate
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the
hospital more often (worse than expected), less often (better than expected), or about the same (as expected),
compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 1 |
Transfusion Summary
Patients with anemia require blood transfusions if their anemia is not managed well by their
dialysis center. This information shows whether Bio-Medical Applications Of Alabama, Inc's rate of transfusions is better than expected,
as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 1 |
Survival Summary
The rate of mortality show you whether patients who were being treated regularly at Bio-Medical Applications Of Alabama, Inc lived longer than
expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared
to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 2 |